Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Chem Pharm Bull (Tokyo) ; 43(12): 2246-52, 1995 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-8582026

RESUMO

Grepafloxacin (1-cyclopropyl-1,4-dihydro-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl )-4-oxo-3-quinoline-carboxylic acid, OPC-17116) (1) exhibits potent and broad-spectrum in vitro and in vivo antibacterial activity. In order to identify the structures of the metabolites of grepafloxacin, 17 possible metabolites were prepared. Among them, 6 compounds were found to be actual metabolites (2a, b, 4a, b and 6a, b) of grepafloxacin in rats, dogs and/or humans. The antibacterial activities of these metabolites were found to be weaker than that of grepafloxacin.


Assuntos
Anti-Infecciosos/metabolismo , Fluoroquinolonas , Piperazinas/metabolismo , Quinolonas/metabolismo , Animais , Anti-Infecciosos/química , Anti-Infecciosos/farmacologia , Biotransformação , Fenômenos Químicos , Físico-Química , Cães , Bactérias Gram-Negativas/efeitos dos fármacos , Bactérias Gram-Positivas/efeitos dos fármacos , Humanos , Testes de Sensibilidade Microbiana , Piperazinas/química , Piperazinas/farmacologia , Quinolonas/química , Quinolonas/farmacologia , Ratos
2.
Antimicrob Agents Chemother ; 38(10): 2340-5, 1994 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-7840567

RESUMO

The antibacterial activity of OPC-17116, a new fluoroquinolone antibacterial agent, against important pathogens that cause respiratory tract infections was evaluated in vitro and in vivo and compared with those of ciprofloxacin, ofloxacin, and norfloxacin. The pharmacokinetic profiles of OPC-17116 were studied in both mice and rats given the drug orally at doses of 50 and 40 mg/kg of body weight, respectively. OPC-17116 showed a high degree of distribution in the lung tissues of both species, with maximum concentrations of 29.6 and 32.0 micrograms/g, respectively. Furthermore, the drug concentrations in lung tissue were about 10 to 15 times greater than the concentrations in plasma. OPC-17116 showed potent antibacterial activity against such pathogens as Staphylococcus aureus, Streptococcus pneumoniae, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, and Moraxella catarrhalis. The MICs of this compound for 90% of these organisms except methicillin-resistant S. aureus and P. aeruginosa ranged from < or = 0.006 to 0.78 microgram/ml. The in vitro antibacterial activity of OPC-17116 was reflected by the efficacy of a single oral dose against systemic bacterial infections in mice. OPC-17116 showed a superior effect against gram-positive bacteria, H. influenzae, and M. catarrhalis. In comparison with the other reference compounds, the efficacy of OPC-17116 was less than that of ciprofloxacin against K. pneumoniae and P. aeruginosa. OPC-17116 showed a greater therapeutic effect than the other drugs against experimental acute pneumonia caused by these organisms in mice or rats. This excellent therapeutic effect against respiratory tract infections may be a result of its high level of distribution in lung tissue.


Assuntos
Anti-Infecciosos/uso terapêutico , Bactérias/efeitos dos fármacos , Fluoroquinolonas , Piperazinas/uso terapêutico , Quinolonas/uso terapêutico , Infecções Respiratórias/tratamento farmacológico , Animais , Infecções Bacterianas/tratamento farmacológico , Masculino , Camundongos , Camundongos Endogâmicos ICR , Testes de Sensibilidade Microbiana , Piperazinas/farmacocinética , Piperazinas/farmacologia , Pneumonia/tratamento farmacológico , Quinolonas/farmacocinética , Quinolonas/farmacologia , Ratos , Ratos Sprague-Dawley , Infecções Respiratórias/microbiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...